XML 1027 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONCENTRATION OF RISK
12 Months Ended
Dec. 31, 2012
Risks and Uncertainties [Abstract]  
Concentration Risk Disclosure [Text Block]
CONCENTRATION OF RISK

Customer and Credit Risk

The Company provides trade credit to its customers in the normal course of business. One payor accounted for approximately 18%, 13% and 15% of revenue during the years ended December 31, 2012, 2011 and 2010, respectively. The majority of the revenue is related to the Infusion Services segment.


Therapy Revenue Risk

The Company sells products related to the Immune Globulin (IVIG) therapy, which represented 19%, 25% and 18% of revenue during the years ended December 31, 2012, 2011 and 2010, respectively. The revenue is related to the Infusion Services segment.